CervoMed Finalizes Phase 3 Trial Design for Neflamapimod in DLB and Reports Positive Phase 2b MRI Analyses
On April 7, 2026, CervoMed Inc. announced a clinical program update for neflamapimod, its lead drug candidate for the treatment of Dementia with Lewy bodies (DLB). The company revealed it has finalized the design of a global, pivotal Phase 3 trial in DLB patients (specifically those without Alzheimerβs disease co-pathology) following alignment with global regulatory authorities. The Phase 3 trial is planned for initiation in the second half of 2026, subject to available funding. Additionally, the company presented new MRI analyses from its Phase 2b RewinD-LB trial, which provided preliminary evidence that neflamapimod may reduce basal forebrain atrophy and improve functional connectivity. CEO John J. Alam noted that the blood biomarker plasma GFAP responded to neflamapimod treatment, correlating with clinical outcomes on the CDR-SB scale. Further detailed MRI data will be presented at the American Academy of Neurology Annual Meeting on April 22, 2026. Neflamapimod is an oral small-molecule p38 MAP kinase alpha inhibitor designed to reverse synaptic dysfunction.